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A B S T R A C T
Acinetobacter baumannii has been identified by the WHO as a high priority pathogen. It can be resistant to
multiple antibiotics and colistin sulphate is often used as a last-resort treatment. However, the potentially se-
vere side-effects of colistin are well documented and this study compared the bactericidal and anti-biofilm
activity of two synthetic nature-inspired antimicrobial peptides, bicarinalin and BP100, with colistin. The min-
imum bactericidal concentration (MBC) against planktonic A. baumannii was approximately 0.5 μg/ml for
colistin sulphate and ∼4 μg/ml for bicarinalin and BP100. A. baumannii commonly occurs as a biofilm and
biofilm removal assay results highlighted that both bicarinalin and BP100 had significantly greater poten-
tial than colistin. Atomic force microscopy (AFM) showed dramatic changes in A. baumannii cell size and
surface conformity when treated with peptide concentrations at and above the MBC. Scanning electron mi-
croscopy (SEM) visualised the reduction of biofilm coverage and cell surface changes as peptide concentra-
tion increased. Liposome assays revealed that these peptides most likely act as pore-forming agents in the
membrane. Bicarinalin and BP100 may be effective therapeutic alternatives to colistin against A. baumannii
infections but further research is required to assess if they elicit cytotoxicity issues in patients.
© 2018.
1. Introduction
It has been widely publicised that by 2050, deaths due to antimi-
crobial resistant (AMR) infections may rise to 10 million per year and
during that time, 300 million people will die from AMR infections [1].
The abuse of currently used antimicrobials, the paucity of new antimi-
crobials progressing successfully through clinical trials and the evolu-
tion of bacterial resistance mechanisms have led to the prospect of re-
turning to the pre-antibiotic era when patients were dying from infec-
tions through minor injuries and routine surgeries. Although the recent
development of novel antibiotics [2,3] has provided reason for opti-
mism, these drugs are generally limited to the treatment of Gram-pos-
itive infections while Gram-negative pathogens remain of significant
concern [4].
Acinetobacter baumannii is one such opportunistic pathogen [5,6]
occurring almost exclusively in the hospital environment and is par-
ticularly prevalent in intensive care and burns units; it has been re-
ported to be responsible for between 2 and 10% of all Gram-negative
nosocomial infections [7]. A member of the ‘ESKAPE’ group [8] of
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pathogens, A. baumannii is able to persist on clinical surfaces by form-
ing biofilms [7,9], an ability that renders bacteria more resistant to
many common antimicrobials [10,11] leading to A. baumannii infec-
tions becoming rapidly more difficult to treat [12]. It is able to persist
for long periods on fomites [7,9] enabling the pathogen to cause wide-
spread epidemic infections in nosocomial settings. Current treatments
include β-lactam antibiotics with the carbapenems typically the treat-
ment of choice [9].
Antimicrobial peptides (AMPs) have been much heralded as alter-
natives to antibiotics due to their ability to destroy multi-drug resistant
(MDR) bacteria [13]. One example is colistin sulphate (colistin), com-
monly used as a last resort treatment for MDR A. baumannii infec-
tions [14]. However, the toxicity of colistin in patients is well known
[13,14] and resistance is increasingly described [15–17] resulting in a
crucial search for improved alternatives.
The aim of this study was to establish and visualise the activity
of two little researched AMPs, bicarinalin and BP100, which may
be appropriate for use instead of colistin to treat MDR A. bauman-
nii infections. Bicarinalin is an amphipathic, C-terminally amidated,
novel antimicrobial peptide derived from the venom of the myrmicine
ant, Tetramorium bicarinatum [18,19]. It consists of a sequence of 20
amino acid residues (KIKIPWGKVKDFLVGGMKAV) with a mol-
ecular weight of 2213.78 g/mol. The action of bicarinalin has been
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ganisms [18,19] and has been found to have good antibacterial activity
compared to other AMPs together with less haemolytic activity.
BP100 is a short C-amidated undecapeptide consisting of 11 amino
acids (KKLFKKILKYL) and a molecular weight of 1420.88 g/mol.
It was originally synthesised by combinatorial chemistry involving
two peptides, cecropin A and melittin [20]. Cecropin A is a member
of the well-researched AMP family, the cecropins, first isolated from
the giant silk moth Hyalophora cecropia. The cecropin family, al-
though susceptible to protease degradation, does not exhibit cytotoxic
effects against human erythrocytes [21,22]. Melittin is a 26 amino
acid, haemolytic alpha helical peptide first purified from the Euro-
pean honeybee in 1958 [23], with demonstrated antibacterial activity
[24]. However, on its own, melittin's strong cytotoxic action makes it
unsuitable for clinical applications [25]. To circumvent cecropin A's
susceptibility to proteolytic degradation and melittin's high cytotoxi-
city, they were combined to produce a derivative, BP100. BP100 ex-
hibits low susceptibility to protease degradation and lower cytotoxi-
city against erythrocytes and fibroblasts [26]. BP100 has been estab-
lished to have good antibacterial activity against several Gram-nega-
tive bacteria [20,22].
It is believed that bicarinalin's antibacterial mechanism is similar
to other AMPs, with its cationic charge, as a result of lysine residues,
naturally attracted to the anionic charged bacterial cell surface. It is
also believed that BP100 interacts with the bacterial cell membrane
via electrostatic attraction to the negatively charged LPS layer, caus-
ing blebbing on the surface leading to a collapse of the outer mem-
brane [20].
The aim of this study was to assess the potential of bicarinalin
and BP100 as alternatives to colistin to treat A. baumannii infections.
The study also aimed to visualise the effects of these antimicrobial
agents on A. baumannii cells and biofilms using scanning electron mi-
croscopy (SEM) and atomic force microscopy (AFM).
2. Materials and methods
2.1. Bacterial culture conditions
Fresh cultures of A. baumannii (ATCC® 19,606) were prepared
by streaking a culti-loop (ThermoFisher Scientific, UK) on freshly
prepared Tryptone Soya Agar (TSA, Oxoid, UK) and incubated for
24 h at 37 °C. Purity was assessed using Gram staining, cell mor-
phology, oxidase and Analytical Profile Index (API, Biomérieux, UK,
20NE kit) testing. A standard growth curve for the A. baumannii was
established to ensure mid-log phase growth and an initial inoculum of
5 × 105 CFU/ml at the start of each experiment.
2.2. Antimicrobial assays
2.2.1. Minimum inhibitory concentration (MIC)
The MIC was determined for each of the antimicrobial agents stud-
ied: colistin (Sigma–Aldrich, UK), bicarinalin (97.7% purity, Gen-
script, USA) and BP100 (98.4% purity, Genscript, USA). 10 ml of
sterile Tryptone Soya Broth (TSB, Oxoid, UK) was inoculated with
2–3 colonies of A. baumannii and incubated overnight at 37 °C and
later diluted to an absorbance that equated to 1 × 106 CFU/ml.
Antimicrobial solutions were prepared and sterilised by filtering
through a 0.2 μm minisart single use sterile filter (Sartorius-Stedim
Biotech, Fisherscientific, UK). Stock solutions (1024 μg/ml) were pre-
pared, taking into account the stated product purity. Reduction of pep-
tide concentration through filtration was not assayed for.
50 μl of each agent, at a stock concentration of 1024 μg/ml, was
added to well 1 of a 96-well microplate (Fisherscientific, UK) and a
two-fold dilution series prepared in wells 2 to 12. 50 μl of inoculated
TSB, containing 1 × 106 CFU/ml of A. baumannii, was then added to
each well resulting in final peptide concentrations from 256 μg/ml to
0.125 μg/ml and a cell density of 5 × 105 CFU/ml. Plates were covered
and incubated in a shaking incubator at 37 °C and 140 rpm for 24 h.
The lowest concentration of peptide where the well was visibly clear
was recorded as the MIC. The entire experiment was carried out three
times in triplicate to give nine datasets and the mean MIC established.
2.2.2. Minimum bactericidal concentration (MBC)
After recording the MIC, spread plates were prepared on TSA us-
ing 100 μl from each clear well. These plates were incubated at 37 °C
for 24 h. The lowest concentration where there was no growth ob-
served on the plate was recorded as the MBC. This was carried out
after each MIC test and therefore three times in triplicate.
2.2.3. Minimum biofilm inhibitory concentration (MBIC)
A 96-well microplate plate containing doubling dilutions of antimi-
crobial was incubated with 5 × 105 CFU/ml A. baumannii for 24 h at
37 °C, 140 rpm. After 24 h, the wells were emptied and washed three
times with ¼ strength Ringer's solution and air dried for 1 h. 1% crys-
tal violet solution was added to each well and left at room tempera-
ture for 10 min. The wells were emptied by pipetting, washed three
times with distilled water, and air dried for 30 min at 37 °C. The stain
was solubilised with 96% ethanol (100 μl). The plate was covered and
shaken at 140 rpm for 30 min 2 μl was removed and the absorbance
of the solution was measured at 590 nm compared to a 96% ethanol
blank. This was replicated three times and the mean calculated. The
percentage biofilm inhibited was calculated by comparing against an
untreated bacterial control. SPSS Statistics 21 (IBM, USA) was used
for the statistical analysis of MBIC results. The samples t-test was
used to find if there was a statistical difference of 95% (p ≤ 0.05, sta-
tistically significant) or 99% (p ≤ 0.01, highly significant).
2.3. Biofilm removal assay
Biofilms of A. baumannii were grown in 36 wells of a 96-well mi-
croplate (test plate) by adding 50 μl sterile TSB and 50 μl of TSB in-
oculated with 1 × 106 CFU/ml culture. Plates were incubated at 37 °C,
140 rpm for 24 h. On a separate 96-well microplate (titration plate)
a doubling dilution series was prepared with 75 μl of TSB and 75 μl
of antimicrobial solution (stock concentration, 8192 μg/ml). The wells
containing biofilm were washed three times with ¼ strength Ringer's
solution and 75 μl sterile TSB was then added to each well. 75 μl from
the titration plate, containing a specific concentration of peptide, was
added to the corresponding well on the test plate. This resulted in each
well containing 150 μl of TSB, which ensured the biofilm was com-
pletely submerged, and the test wells containing a doubling dilution
series of antimicrobial (2048 μg/ml to 2 μg/ml). 150 μl sterile TSB
was added to the negative control wells. Plates were covered and incu-
bated in a shaking incubator for 24 h at 37 °C, 140 rpm. After incuba-
tion, the wells were emptied by tipping onto absorbent paper, washed
three times with 200 μl ¼ strength Ringer's solution and air fixed for
1 h under aseptic conditions.
The percentage of biofilm removal was quantified by measuring
the absorbance after applying crystal violet stain as described pre-
viously. The absorbance (at 590 nm) was determined for each sam-
ple. Biofilm reduction (%) was determined by comparison of the ab-
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SPSS Statistics 21 software (IBM, USA) was used to assess the
significance of the biofilm removal assay results. The samples t-test
was applied to assess the statistical difference of 95% (p ≤ 0.05) which
was considered as statistically significant or 99% (p ≤ 0.01) which
was considered highly significant.
2.4. Scanning electron microscopy
A. baumannii biofilms were prepared in 150 μl TSB in 96-well mi-
croplates. Calgary Biofilm Device (CBD) lids (Nunc-TSP Screening
Plate Lids, ThermoScientific, UK) were placed on the plates with the
polystyrene pegs protruding into the broth. Plates were sealed and in-
cubated at 37 °C, 140 rpm for 24 h. After incubation, the pegs were
washed by submerging in 200 μl of sterile ¼ strength Ringer's solution
and leaving for 2 min and this process was repeated twice more. Each
well was then filled with 100 μl sterile TSB.
Antimicrobial challenge plates were prepared, containing agent
concentrations of 1 μg/ml, 10 μg/ml and 100 μg/ml. The CBD lid
was placed onto this challenge plate, covered and incubated at 37 °C,
140 rpm for 24 h. After 24 h the pegs were washed by submerging the
CBD lid in 250 μl of sterile ¼ strength Ringer's solution and leaving
for 2 min and subsequently repeated twice more.
0.1 M sodium cacodylate buffer was prepared to give a pH reading
of 7.2. The CBD pegs were then submerged in this solution for 3 min.
2.5% glutaraldehyde solution was prepared. The CBD lid was
immersed in the buffer, covered and left at ambient temperature
(21 ± 2 °C) for 40 min. The CBD lid was then removed and twice
washed in distilled water for 2 min. Biofilms were then dehydrated
sequentially by placing twice into 50% methanol (Fisher Scientific,
UK), 70% methanol and finally 100% methanol. CBD lids were left in
each solution for 2 min. Pegs were subsequently air dried for 4 days.
Pegs were removed from the CBD lid and mounted onto 0.5″
aluminium specimen stubs, fixed using carbon adhesive discs (Agar
Scientific, UK). After mounting, the carbon tabs were painted with
graphite and the pegs were coated with approximately 15–20 nm of
platinum. A. baumannii biofilms on the surface of the pegs were visu-
alised using a FEI Quanta FEG 650 Scanning Electron Microscope.
2.5. Atomic force microscopy
Atomic force microscopy (AFM) was used to obtain topographic
images of A. baumannii cells when subjected to peptide concentra-
tions equating to ½ MBC, MBC and 2× MBC. These concentrations
were 0.25, 0.5 and 1 μg/ml for colistin and 2, 4 and 8 μg/ml for both
bicarinalin and BP100. 150 μl suspensions, containing inoculated TSB
with A. baumannii cell density of 5 × 105 CFU/ml and appropriate
concentrations of antimicrobial, were prepared in 96-well microplates.
Plates were incubated at 37 °C, 140 rpm for 2 h.
After incubation the suspension was pipetted onto a poly-L-lysine
coated slide (Sigma Aldrich, UK) and left at ambient room tempera-
ture (21 ± 2 °C) for 20 min. Slides were rinsed with distilled water and
left to air dry.
Images were captured using a Bioscope Catalyst AFM (Bruker,
Germany) operated in PeakForce tapping mode using ScanAsyst-air
tips (Bruker, Germany). Images were acquired on an area of 4 μm2 at
a scan rate of 0.5 Hz.
2.6. Vesicle leakage assays
Liposomes were made from lipids extracted from A. baumannii. A.
baumannii cultured at 37 °C was harvested and a total lipid extraction
conducted as described by Bligh & Dyer [27], with an extra step to
extract any lipid remaining in the supernatant plus 3× washing steps
with 1 M KCl. The extracted lipid was stored in chloroform at −20 °C.
A Stewart lipid assay was conducted to quantify the lipid extracted.
2 mg lipid, dried from chloroform in a round-bottomed flask, was
hydrated in 1 ml 100 mM 5 (6)-carboxyfluorescein (Sigma Aldrich,
UK) and allowed to hydrate for 25 min with occasional shaking. The
resulting suspension was extruded through a 400 nm filter and then a
100 nm Nuclepore track-etched polycarbonate membrane (Whatman,
UK) using a mini-extruder (Avanti Polar Lipids, USA) at 37 °C. The
extruded liposomes were then washed 3 times to remove un-encapsu-
lated carboxyfluorescein by pelleting at 100,000 g and re-suspending
in 50 mM Tris–HCl buffer and 10 mM NaCl at pH 7.3 before final
re-suspension in 1 ml of the same buffer.
6.25 μl of the above liposome suspension was added to 500 μl
aliquots of antimicrobial peptide solutions at the following concen-
trations: 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 & 512 μg/ml in
the above Tris buffer. An additional concentration of 0.125 μg/ml was
used for colistin due to its lower MIC. 100 μl aliquots were trans-
ferred to black 96-well microplates for fluorescence measurements
at 490 nm excitation and 520 nm emission using an Infinite 200Pro
(Tecan, Switzerland). Carboxyfluorescein leakage was measured rela-
tive to the same quantity of liposomes suspended in 1% SDS follow-
ing approximately 30 min exposure to the agent.
3. Results
3.1. Antimicrobial assays
MIC and MBC values were determined to be 0.5 μg/ml
(0.43 μmol/L) for colistin, 4 μg/ml (1.8 μmol/L) for bicarinalin and
4 μg/ml (2.8 μmol/L) for BP100 (data not shown). Fig. 1 shows that
the MBIC was found to be similar to the MIC and MBC for each
agent with 90% of biofilm formation inhibited at 0.5 μg/ml colistin
Fig. 1. MBIC for colistin sulphate, bicarinalin and BP100. A. baumannii was subjected
to a doubling dilution series (2–2048 μg/ml) of antimicrobial for 24 h. After washing
and air fixing for 1 h, samples were stained with 1% crystal violet. After 10 min the
stain was solubilised with 96% ethanol and the absorbance at 590 nm was read against
a 96% ethanol blank. The percentage biofilm inhibited was calculated by comparing
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and 4 μg/ml bicarinalin and BP100. This also showed that at con-
centrations below the peptides' respective MBCs, biofilm formation
was possible with only 36% biofilm inhibition for colistin, 23% for
bicarinalin and 20% for BP100. Fig. 2 shows the eradication of a
24-h biofilm when subjected to increasing concentrations of peptide.
At 1 μg/ml of colistin, 27% of biofilm was removed. As the peptide
concentration increased, more biofilm was eradicated with 52% re-
moved at 512 μg/ml. Bicarinalin removed 18% at 1 μg/ml which then
increased to 70% at 128 μg/ml; no further biofilm eradication was
observed with higher concentrations. BP100 removed 17% at 1 μg/
ml which remained low until 16 μg/ml. Above this concentration, the
biofilm removed increased from 27% at 32 μg/ml to 76% at 512 μg/
ml, higher than both colistin and bicarinalin, to 93% at 2048 μg/ml.
3.2. Microscopy
SEM (Fig. 3) and AFM (Fig. 4) provide visualisation of the effects
of these agents on A. baumannii cells. Fig. 3 demonstrates that, as the
concentration of the agents increases, the morphological changes to
the cells become more pronounced including evidence of blebbing and
a more variable cell shape with shrinkage and membrane disruption.
The coverage across the surface also reduces: with no addition of an-
timicrobial agent the cells are packed closely together and cover the
whole interface; as the peptide concentration increases visible gaps are
seen between clusters of cells. The cellular morphological changes are
also observed in Fig. 4 by AFM. Blebbing is observed, causing var-
ied cell shape and shrinkage at the MBC concentrations, and the cells
differ greatly compared to the cocci-bacilli shaped cells seen with no
antimicrobial treatment and below the MBC.
3.3. Vesicle leakage assays
To determine the mechanism of action of the antimicrobial agents,
a vesicle leakage assay was performed. Liposomes produced from
lipids extracted from A. baumannii (Fig. 5) all leaked carboxyfluores-
cein in the presence of the antimicrobials. The concentration of agent
causing half-maximal leakage for each agent was ∼1.75 μg/ml for
colistin, ∼2.75 μg/ml for BP100 and ∼2 μg/ml for bicarinalin (given
maximal leakage of 70%, 65% and 56% respectively). Vesicle leak
Fig. 2. Percentage biofilm eradication by colistin sulphate, bicarinalin and BP100. A.
baumannii biofilms were grown for 24 h and then subjected to a doubling dilution series
(2–2048 μg/ml) of antimicrobial for 24 h. After washing and air fixing for 1 h, samples
were stained with 1% crystal violet. After 10 min the stain was solubilised with 96%
ethanol and the absorbance at 590 nm was read against a 96% ethanol blank. The per-
centage biofilm eradicated was calculated by comparing against an untreated bacterial
control. The experiment was carried out twice in triplicate.
age results support the proposal that these agents exert effects on the
bacterial cell membrane causing significant disruption to the cell sur-
face (as shown in Fig. 4) and eventually cell lysis (as shown in Fig. 3).
4. Discussion
A. baumannii susceptibility to colistin was similar to that deter-
mined by Li et al. [28] and Sauger [29], confirming that A. bauman-
nii 19,606 strain is colistin susceptible as defined by The Clinical
and Laboratory Standards Institute. Bicarinalin results were compared
with those of Rifflet [18] and Téné [19] who investigated Cronobacter
spp., Enterobacter spp. and Staphylococcus spp., Results suggest that
A. baumannii is generally more susceptible to bicarinalin than these
other bacteria. Antimicrobial activity results for BP100 against A. bau-
mannii 19,606 were comparable to other bacteria in previous studies
[20,21].
Although the MBC for both bicarinalin and BP100 was 4 μg/ml,
the molar concentration of peptide differed (1.8 μmol/L for bicarinalin
and 2.8 μmol/L for BP100). This is primarily due to the differences in
molecular weight (bicarinalin 2213.78 g/mol, BP100 1420.88 g/mol)
indicating that, although BP100 is smaller in length, it exerts a simi-
lar inhibitory and potent effect on A. baumannii. By comparison, col-
istin has a MBC of 0.43 μmol/L (with the smallest molecular weight,
1155.4 g/mol).
MBIC results demonstrated that, at the MBC for all three antimi-
crobials studied, there was less than 10% biofilm formed compared
to the control. Additionally, at concentrations of antimicrobial agents
equal to ½ MBC (2 μg/ml for bicarinalin and BP100, 0.25 μg/ml for
colistin) there was less inhibition of biofilm formation with 77% of
biofilm formed in the presence of bicarinalin, 95% in BP100 and 64%
in colistin. This highlights that even below their respective MBCs, bi-
carinalin and colistin have some potential to prevent biofilm forma-
tion but BP100 had very little, possibly due to differences in size and
mechanism of action.
Biofilm eradication results indicated that bicarinalin is superior at
eradicating A. baumannii biofilms than colistin above its MBC and
both bicarinalin and BP100 are more effective at concentrations above
128 μg/ml. Colistin was more effective at removing A. baumannii
biofilms at low concentrations; this was as expected due to its lower
MBC which is nearly an order of magnitude less than bicarinalin and
BP100. However, the maximum biofilm removed was only ∼50% at
512 μg/ml. Bicarinalin was the most effective between 8 μg/ml, where
it removed ∼40% of the biofilm, and 128 μg/ml, where it eradicated
70% of the biofilm. Any further increase of concentration had no addi-
tional significant effect on the biofilm. The removal activity of BP100
started slowly and at 16 μg/ml it had removed only 20% of the biofilm,
half that of colistin. Above 16 μg/ml, BP100 increased relatively lin-
early to exceed bicarinalin activity above 512 μg/ml. At 2048 μg/ml,
the highest concentration tested, BP100 had eradicated ∼95% of the
biofilm. Colistin had the most biofilm removal activity, as expected,
at low concentrations of 1–4 μg/ml, below the MBC of bicarinalin and
BP100. Bicarinalin was the most active between 8 and 128 μg/ml and
BP100 was the most effective from 256 to 2048 μg/ml. The superior
performance of bicarinalin, and particularly that of BP100 on biofilms
at higher concentrations, was not anticipated especially considering
the MBC is significantly higher than colistin.
The SEM has been widely used to image bacterial biofilms [30,31],
revealing, with increasing concentrations of peptide, progressive
changes in cellular shape and structure of the biofilm. Membrane
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Fig. 3. SEM Images of A. baumannii biofilms. Biofilms were grown for 24 h then treated for a further 24 h with colistin (A), bicarinalin (B) and BP100 (C). Control images, no
antimicrobial (1), 1 μg/ml (2), 10 μg/ml (3), 100 μg/ml (4). Scale bars on main images are 1 μm, 10 μm on inset images.
and at 1 μg/ml concentrations for each agent in this study. Pili or cellu-
lar filaments between cells have been previously documented between
cells within biofilms [32,33]. At the higher concentrations of 10 μg/
ml and 100 μg/ml, these protrusions were not visible suggesting the
inability of the cells to form pili at these concentrations [34]. Fig. 3
clearly shows that as the concentration of agent is increased, the cell
shape becomes less regular and the surface coverage is decreased.
The effect of the antimicrobials on A. baumannii was visualised by
AFM. Fig. 4 highlights that, below the peptide MBC, the coccus-bacil-
lus cell shape is conserved. However, at concentrations at and above
the MBC, the cell surface, conformation and size are drastically af-
fected. At the highest concentrations tested there is evidence of severe
disruption to the cell surface, cytoplasmic leakage and lysed cells.
Membrane disruption caused by peptide activity is noted from var-
ious studies [20,35–37]. In this study, indentations and pores are seen
in the bacterial surface with resulting cytoplasmic leakage and debris,
suggesting loss of turgor pressure [38]. As the peptide concentration
increased, more intense membrane perturbation and cytoplasmic leak-
age were visualised. Similar observations were described by Li et al.
[35].
Although AFM imaging of bacterial cells in air is a widely used
technique [20,39], it can lead to dehydration of the cell and changes in
the cell surface that were not directly caused by peptide activity. How-
ever, all images have been compared to the control of untreated cells.
The dye leakage assay reflects the relative potency of these pep-
tides against A. baumannii, suggesting that the peptides mediate their
effects through the formation of pores in the membrane although it
likely reflects planktonic growth more accurately than biofilm-like
structures. It cannot be directly concluded whether the peptides exert
their effects on the cytoplasmic or outer membrane of the cell. The
visualised bacterial cell morphological changes seen in SEM (Fig. 3)
and AFM (Fig. 4) images are likely to relate to outer membrane dis-
order while the vesicle leakage assay may represent disruption to the
cytoplasmic membrane.
Overall the results support the proposal that bicarinalin and BP100
could be used to control infections caused by biofilm-producing
prokaryotes. However, Torcato et al. [40] observed 50% cytotoxicity
against HELA cells at 49.2 ± 1.4 μmol/L for BP100 which is higher
than the MBC observed here (2.8 μmol/L) but lower than the con-
centrations needed for antibiofilm activity, suggesting that clinical an-
tibiofilm activity of BP100 may be unlikely. Colistin performs well
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Fig. 4. AFM Images of A. baumannii cells after being treated with colistin (A), bicarinalin (B) and BP100 (C) for 2 h and fixed onto a glass slide coated with poly-L-lysine. Control
images, no antimicrobial (1), 1/2 MBC (2), MBC (3), 2× MBC (4). Images were 4 μm2 and 256 lines at 0.5 Hz. Scale bars are 1 μm.
Fig. 5. The relative leakage of carboxyfluorescein from liposomes made from A. bau-
mannii total lipid extract in the presence of increasing concentrations of the three an-
timicrobial agents. Error bars show the standard error around the mean of 3 replicates.
against biofilms. As A. baumannii is able to form biofilms, it is essen-
tial that investigations into the efficacy of novel agents are performed
rigorously on biofilms.
The results indicate that bicarinalin and BP100 both have similar
bactericidal and generally better anti-biofilm activity against A. bau
mannii than colistin, with evidence supporting the idea that these
peptides mediate their effects through the formation of pores in the
membrane. This is encouraging but cytotoxic studies will determine
whether, at these concentrations, bicarinalin and BP100 can be used in
clinical treatment.
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